We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IVDA Stock Declines 43.4% as Q2 Loss Widens, Revenues Fall Y/Y
Read MoreHide Full Article
Shares of Iveda Solutions, Inc. (IVDA - Free Report) have fallen 43.4% since reporting second-quarter 2026 results. This compares with the S&P 500 index’s 1.5% decline over the same period. Over the past month, the stock has risen 24.9% compared with the S&P 500’s 4.8% return.
Earnings & Revenue Performance
The company’s second-quarter revenues were $801,846, down 48% from $1.53 million a year earlier. Equipment sales, the company’s main revenue source, fell 50% to $723,243, while service revenues were nearly unchanged at $78,603. The net loss widened 41% to $793,469 from $564,249. However, loss per share narrowed to 7 cents from 20 cents because weighted-average shares outstanding increased to 11.82 million from 2.84 million.
Iveda Solutions, Inc. Price, Consensus and EPS Surprise
Gross profit slipped only 1% year over year to $438,562 despite the sharp revenue decline, as the cost of revenues dropped 66% to $363,284. Consequently, the gross margin improved to 55% from 29%, showing a substantially more favorable sales mix.
Operating expenses increased 18% year over year to $1.15 million. General and administrative expenses rose 14% to $1.05 million, while research and development expenses climbed 90% to $97,769. The operating loss therefore widened 33% to $710,123 from $532,360. Interest income and other items, net, contributed $30,750 against expenses of $2,111 in the prior-year quarter, but a $114,096 income-tax provision added pressure.
For the first half of 2026, revenues declined 24% year over year to $2.30 million, but gross profit increased 27% to $933,770 and the gross margin expanded to 41% from 24%. The six-month net loss narrowed 2% to $1.33 million from $1.36 million, as improved gross profit outweighed a 5% rise in operating expenses.
Customer concentration remains high. Three customers generated 72% of first-half revenues, with National Chung Shan Institute of Science and Technology alone accounting for 41%. Four customers represented 93% of accounts receivable as of June 30, exposing results and collections to a small group of counterparties.
Geographic Performance
Taiwan remained the dominant operation, generating $730,280, or about 91% of quarterly revenues. That fell 36% year over year, while U.S. revenues fell 81% to $71,566. Taiwan’s gross margin rose to 52% from 30%, while the U.S. gross margin reached 84% compared with 27%.
Taiwan posted operating income of $160,485, down 17% from $192,213. In contrast, the U.S. operating loss widened 20% to $870,608 from $724,572 in the prior-year quarter, offsetting Taiwan’s profitability and underscoring the continued burden of the domestic cost base.
Factors Influencing Headline Numbers
Management attributed the revenue decline mainly to lower equipment sales at Iveda Taiwan caused by delivery timing on long-term government contracts. The explanation indicates that project scheduling, rather than solely lost demand, affected recognized revenues, although the filing did not quantify when delayed deliveries may convert into sales.
The gross-margin expansion reflected higher-margin contract sales in Taiwan and the United States. However, higher operating costs absorbed that benefit. Management said that the expense increase primarily reflected investor-relations activities in the U.S. operation. The company’s dual model — hardware and software licensing in the United States and project-based enterprise and government work in Taiwan — also leaves quarterly results sensitive to the timing and mix of large contracts.
Liquidity & Management Outlook
Cash and cash equivalents totaled $4.76 million as of June 30, 2026, down from $5.16 million as of Dec. 31, 2025. Net cash used in operations increased to $2.36 million for the first half from $1.46 million a year earlier. Management tied the outflow mainly to the $1.33-million six-month net loss and a $909,913 increase in deferred cost of goods related to Taiwan government-entity sales.
Financing activities supplied $1.9 million during the first half, including $1.6 million from a February 2026 direct stock offering and $0.3 million from warrant exercises. Management expects available cash to fund its current operating plan for at least 12 months from the filing’s issuance.
Other Developments
On June 16, holders exercised 825,000 Series X warrants at 35 cents each, providing Iveda with net proceeds of $272,863. The company also issued 100,000 shares for services valued at $58,000 during the first half of 2026.
View the Zacks #1 Rank List
Image: Bigstock
IVDA Stock Declines 43.4% as Q2 Loss Widens, Revenues Fall Y/Y
Shares of Iveda Solutions, Inc. (IVDA - Free Report) have fallen 43.4% since reporting second-quarter 2026 results. This compares with the S&P 500 index’s 1.5% decline over the same period. Over the past month, the stock has risen 24.9% compared with the S&P 500’s 4.8% return.
Earnings & Revenue Performance
The company’s second-quarter revenues were $801,846, down 48% from $1.53 million a year earlier. Equipment sales, the company’s main revenue source, fell 50% to $723,243, while service revenues were nearly unchanged at $78,603. The net loss widened 41% to $793,469 from $564,249. However, loss per share narrowed to 7 cents from 20 cents because weighted-average shares outstanding increased to 11.82 million from 2.84 million.
Iveda Solutions, Inc. Price, Consensus and EPS Surprise
Iveda Solutions, Inc. price-consensus-eps-surprise-chart | Iveda Solutions, Inc. Quote
Other Key Business Metrics
Gross profit slipped only 1% year over year to $438,562 despite the sharp revenue decline, as the cost of revenues dropped 66% to $363,284. Consequently, the gross margin improved to 55% from 29%, showing a substantially more favorable sales mix.
Operating expenses increased 18% year over year to $1.15 million. General and administrative expenses rose 14% to $1.05 million, while research and development expenses climbed 90% to $97,769. The operating loss therefore widened 33% to $710,123 from $532,360. Interest income and other items, net, contributed $30,750 against expenses of $2,111 in the prior-year quarter, but a $114,096 income-tax provision added pressure.
For the first half of 2026, revenues declined 24% year over year to $2.30 million, but gross profit increased 27% to $933,770 and the gross margin expanded to 41% from 24%. The six-month net loss narrowed 2% to $1.33 million from $1.36 million, as improved gross profit outweighed a 5% rise in operating expenses.
Customer concentration remains high. Three customers generated 72% of first-half revenues, with National Chung Shan Institute of Science and Technology alone accounting for 41%. Four customers represented 93% of accounts receivable as of June 30, exposing results and collections to a small group of counterparties.
Geographic Performance
Taiwan remained the dominant operation, generating $730,280, or about 91% of quarterly revenues. That fell 36% year over year, while U.S. revenues fell 81% to $71,566. Taiwan’s gross margin rose to 52% from 30%, while the U.S. gross margin reached 84% compared with 27%.
Taiwan posted operating income of $160,485, down 17% from $192,213. In contrast, the U.S. operating loss widened 20% to $870,608 from $724,572 in the prior-year quarter, offsetting Taiwan’s profitability and underscoring the continued burden of the domestic cost base.
Factors Influencing Headline Numbers
Management attributed the revenue decline mainly to lower equipment sales at Iveda Taiwan caused by delivery timing on long-term government contracts. The explanation indicates that project scheduling, rather than solely lost demand, affected recognized revenues, although the filing did not quantify when delayed deliveries may convert into sales.
The gross-margin expansion reflected higher-margin contract sales in Taiwan and the United States. However, higher operating costs absorbed that benefit. Management said that the expense increase primarily reflected investor-relations activities in the U.S. operation. The company’s dual model — hardware and software licensing in the United States and project-based enterprise and government work in Taiwan — also leaves quarterly results sensitive to the timing and mix of large contracts.
Liquidity & Management Outlook
Cash and cash equivalents totaled $4.76 million as of June 30, 2026, down from $5.16 million as of Dec. 31, 2025. Net cash used in operations increased to $2.36 million for the first half from $1.46 million a year earlier. Management tied the outflow mainly to the $1.33-million six-month net loss and a $909,913 increase in deferred cost of goods related to Taiwan government-entity sales.
Financing activities supplied $1.9 million during the first half, including $1.6 million from a February 2026 direct stock offering and $0.3 million from warrant exercises. Management expects available cash to fund its current operating plan for at least 12 months from the filing’s issuance.
Other Developments
On June 16, holders exercised 825,000 Series X warrants at 35 cents each, providing Iveda with net proceeds of $272,863. The company also issued 100,000 shares for services valued at $58,000 during the first half of 2026.